Congress just passed the Inflation Reduction Act, with prescription drug policies including government price setting, inflationary penalties, Part D benefit redesign, and a $35 insulin copay cap in Medicare. This legislation will have substantial implications for manufacturers, physicians and patients. ADVI’s policy and analytics team can explain how these changes will affect your business, and what you can do to prepare. For bill highlights, check out our ADVI Instant.